OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Implementation of a liver health check in people with type 2 diabetes
Kushala Abeysekera, Luca Valenti, Zobair M. Younossi, et al.
The Lancet. Gastroenterology & hepatology (2023) Vol. 9, Iss. 1, pp. 83-91
Open Access | Times Cited: 30
Kushala Abeysekera, Luca Valenti, Zobair M. Younossi, et al.
The Lancet. Gastroenterology & hepatology (2023) Vol. 9, Iss. 1, pp. 83-91
Open Access | Times Cited: 30
Showing 1-25 of 30 citing articles:
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 361
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 361
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 65
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 65
Non-invasive testing and risk-stratification in patients with MASLD
Mirko Zoncapé, Antonio Liguori, Emmanuel Tsochatzis
European Journal of Internal Medicine (2024) Vol. 122, pp. 11-19
Closed Access | Times Cited: 40
Mirko Zoncapé, Antonio Liguori, Emmanuel Tsochatzis
European Journal of Internal Medicine (2024) Vol. 122, pp. 11-19
Closed Access | Times Cited: 40
Steatotic liver disease
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis, et al.
The Lancet (2024) Vol. 404, Iss. 10464, pp. 1761-1778
Closed Access | Times Cited: 36
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis, et al.
The Lancet (2024) Vol. 404, Iss. 10464, pp. 1761-1778
Closed Access | Times Cited: 36
Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease
Xiaolong Qi, Jie Li, Cyrielle Caussy, et al.
Hepatology (2024)
Open Access | Times Cited: 21
Xiaolong Qi, Jie Li, Cyrielle Caussy, et al.
Hepatology (2024)
Open Access | Times Cited: 21
Effect and mechanism of insoluble dietary fiber on postprandial blood sugar regulation
Gaopeng Zhang, Dan Wang, Yangyue Ding, et al.
Trends in Food Science & Technology (2024) Vol. 146, pp. 104354-104354
Closed Access | Times Cited: 20
Gaopeng Zhang, Dan Wang, Yangyue Ding, et al.
Trends in Food Science & Technology (2024) Vol. 146, pp. 104354-104354
Closed Access | Times Cited: 20
Envisioning how to advance the MASH field
Alina M. Allen, Zobair M. Younossi, Anna Mae Diehl, et al.
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 15
Alina M. Allen, Zobair M. Younossi, Anna Mae Diehl, et al.
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 15
Diabetes as a risk factor for MASH progression
Sofiya Gancheva, Michael Roden, Laurent Castéra
Diabetes Research and Clinical Practice (2024) Vol. 217, pp. 111846-111846
Open Access | Times Cited: 12
Sofiya Gancheva, Michael Roden, Laurent Castéra
Diabetes Research and Clinical Practice (2024) Vol. 217, pp. 111846-111846
Open Access | Times Cited: 12
Non-invasive tests for alcohol-associated liver disease
Mads Israelsen, Wiramon Rungratanawanich, Maja Thiele, et al.
Hepatology (2024) Vol. 80, Iss. 6, pp. 1390-1407
Closed Access | Times Cited: 10
Mads Israelsen, Wiramon Rungratanawanich, Maja Thiele, et al.
Hepatology (2024) Vol. 80, Iss. 6, pp. 1390-1407
Closed Access | Times Cited: 10
Population screening for cirrhosis
Maja Thiele, Elisa Pose, Adrià Juanola, et al.
Hepatology Communications (2024) Vol. 8, Iss. 9
Open Access | Times Cited: 8
Maja Thiele, Elisa Pose, Adrià Juanola, et al.
Hepatology Communications (2024) Vol. 8, Iss. 9
Open Access | Times Cited: 8
LiverRisk score: An accurate, cost-effective tool to predict fibrosis, liver-related, and diabetes-related mortality in the general population
Shanghao Liu, Xiaohan Chen, Xuanwei Jiang, et al.
Med (2024) Vol. 5, Iss. 6, pp. 570-582.e4
Closed Access | Times Cited: 7
Shanghao Liu, Xiaohan Chen, Xuanwei Jiang, et al.
Med (2024) Vol. 5, Iss. 6, pp. 570-582.e4
Closed Access | Times Cited: 7
Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials
Takumi Kawaguchi, Kenta Murotani, Hiromitsu Kajiyama, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 9, pp. 836-848
Open Access | Times Cited: 6
Takumi Kawaguchi, Kenta Murotani, Hiromitsu Kajiyama, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 9, pp. 836-848
Open Access | Times Cited: 6
Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study
Katrine Prier Lindvig, Katrine Thorhauge, Aleksander Krag, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 10, Iss. 1, pp. 55-67
Closed Access | Times Cited: 4
Katrine Prier Lindvig, Katrine Thorhauge, Aleksander Krag, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 10, Iss. 1, pp. 55-67
Closed Access | Times Cited: 4
Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study
Andrea Lindfors, Rickard Strandberg, Hannes Hagström
The Lancet. Gastroenterology & hepatology (2024)
Closed Access | Times Cited: 4
Andrea Lindfors, Rickard Strandberg, Hannes Hagström
The Lancet. Gastroenterology & hepatology (2024)
Closed Access | Times Cited: 4
Start small, think big: MicroRNAs in diabetes mellitus and relevant cardiorenal-liver metabolic health spectrum
Junren Chen, Meng Luo, Ziwei Xing, et al.
Metabolism (2025) Vol. 165, pp. 156153-156153
Closed Access
Junren Chen, Meng Luo, Ziwei Xing, et al.
Metabolism (2025) Vol. 165, pp. 156153-156153
Closed Access
Comparison Between the Impact of Diabetes Mellitus on Liver Diseases and Vice Versa Among Saudi and Egyptian Patients
M. R. Mahmoud, Somia Ibrahim, Mona M. Shahien, et al.
Healthcare (2025) Vol. 13, Iss. 4, pp. 376-376
Open Access
M. R. Mahmoud, Somia Ibrahim, Mona M. Shahien, et al.
Healthcare (2025) Vol. 13, Iss. 4, pp. 376-376
Open Access
A call to action to address the steatotic liver disease public health threat in Barcelona
Jeffrey V. Lazarus, J Emilio Miralles-Sanchez, Leire Agirre-Garrido, et al.
The Lancet Regional Health - Europe (2025) Vol. 52, pp. 101272-101272
Closed Access
Jeffrey V. Lazarus, J Emilio Miralles-Sanchez, Leire Agirre-Garrido, et al.
The Lancet Regional Health - Europe (2025) Vol. 52, pp. 101272-101272
Closed Access
Liver Fibrosis Testing in Patients With Type 2 Diabetes: The Time Is Now
Mirko Zoncapé, Emmanuel Tsochatzis
Diabetes Care (2025) Vol. 48, Iss. 6, pp. 871-873
Closed Access
Mirko Zoncapé, Emmanuel Tsochatzis
Diabetes Care (2025) Vol. 48, Iss. 6, pp. 871-873
Closed Access
DiabetesLiver score: A non-invasive algorithm for advanced liver fibrosis and liver-related outcomes in type 2 diabetes mellitus population
Chuan Liu, Jie Shen, Jie Li, et al.
Med (2025), pp. 100700-100700
Closed Access
Chuan Liu, Jie Shen, Jie Li, et al.
Med (2025), pp. 100700-100700
Closed Access
Elevated FIB-4 Is Associated with Higher Rates of Cardiovascular Disease and Extrahepatic Cancer History in Patients with Type 2 Diabetes Mellitus
Dimitrios Karagiannakis, Katerina Stefanaki, Foteini Petrea, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 823-823
Open Access | Times Cited: 3
Dimitrios Karagiannakis, Katerina Stefanaki, Foteini Petrea, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 823-823
Open Access | Times Cited: 3
Expanding diagnostic and therapeutic horizons for MASH: Comparison of the latest and conventional therapeutic approaches
Georgia Anastasiou, Konstantinos Stefanakis, Michael A. Hill, et al.
Metabolism (2024), pp. 156044-156044
Closed Access | Times Cited: 3
Georgia Anastasiou, Konstantinos Stefanakis, Michael A. Hill, et al.
Metabolism (2024), pp. 156044-156044
Closed Access | Times Cited: 3
Liver steatosis linked to type 2 diabetes outcomes
Neeraj Bhala
BMJ (2024), pp. q309-q309
Closed Access | Times Cited: 2
Neeraj Bhala
BMJ (2024), pp. q309-q309
Closed Access | Times Cited: 2
GDF-15 improves the predictive capacity of Steatotic liver disease non-invasive tests for incident morbidity and mortality risk for cardio-renal-metabolic diseases and malignancies
Michail Kokkorakis, Pytrik Folkertsma, José Castela Forte, et al.
Metabolism (2024), pp. 156047-156047
Closed Access | Times Cited: 2
Michail Kokkorakis, Pytrik Folkertsma, José Castela Forte, et al.
Metabolism (2024), pp. 156047-156047
Closed Access | Times Cited: 2
Automated Fibrosis-4 Index: Simplifying Non-Alcoholic Fatty Liver Disease for Diabetologists
Mona Ismail, Reem Al Argan, Yasir Elamin, et al.
Medicina (2024) Vol. 60, Iss. 8, pp. 1278-1278
Open Access | Times Cited: 2
Mona Ismail, Reem Al Argan, Yasir Elamin, et al.
Medicina (2024) Vol. 60, Iss. 8, pp. 1278-1278
Open Access | Times Cited: 2
Transitioning FIB-4 Score: From Fibrosis Screening Tool to Key Biomarker for Clinical Endpoints
David Petroff, Thomas Berg, Johannes Wiegand
Journal of Hepatology (2024) Vol. 81, Iss. 5, pp. e228-e229
Closed Access | Times Cited: 1
David Petroff, Thomas Berg, Johannes Wiegand
Journal of Hepatology (2024) Vol. 81, Iss. 5, pp. e228-e229
Closed Access | Times Cited: 1
